Asset profile
PF-06946860
Monoclonal antibody
Evidence outlook · lead readout
NCT04299048 · Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04299048: Every participant in this small study received the same drug with no placebo or control group, so the reported adverse-event and laboratory-abnormality rates cannot be attributed to the drug versus the underlying advanced cancer and cachexia; all patients had an adverse event and roughly 40% had a serious adverse event, including one death.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.